Epigenetic Combination Therapy Could Overcome Treatment Resistance in Epithelioid Sarcomas and Rhabdoid Tumors

Epithelioid sarcoma, a rare aggressive cancer that usually strikes young adults, and rhabdoid tumors, which affect children, have long been difficult to treat. But the outlook for people with these subtypes of soft tissue sarcoma brightened in 2020 when the Food and Drug Administration approved a targeted therapy called tazemetostat (Tazverik) for certain patients.

Read more: https://www.mskcc.org/news/epigenetic-combination-therapy-could-overcome-treatment-resistance-in-epithelioid-sarcomas-and-rhabdoid-tumors